Description
Novel anxiolytic compoundsAbstract: The present invention relates to chemical compounds of general formula (I):
which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
US20180105523A1 - United States
Application US15/844,264 events
2006-10-16 Priority to US85198306P
2007-10-16 Priority to PCT/AU2007/001566
2009-11-23 Priority to US31187209A
2012-09-14 Priority to US13/617,153
2013-09-18 Priority to US14/030,808
2014-11-05 Priority to US14/533,808
2017-01-04 Priority to US15/398,472
2017-12-15 Priority to US15/844,264
2017-12-15 Application filed by Bionomics Ltd
2018-04-19 Publication of US20180105523A1
2020-05-08 Assigned to OXFORD FINANCE LLC, AS COLLATERAL AGENT
2021-02-05 Assigned to BIONOMICS LIMITED
2021-02-11 Assigned to BIONOMICS LIMITED
2021-02-11 Assigned to THE WALTER & ELIZA HALL INSTITUTE OF MEDICAL RESEARCH
2021-02-11 Assigned to BIONOMICS LIMITED
2021-03-23 Application granted
2021-03-23 Publication of US10954231B2
2021-04-30 Assigned to BIONOMICS, LTD
| Period | 19 Apr 2018 |
|---|---|
| Held at | Bionomics Ltd, Australia, South Australia |
| Degree of Recognition | National |